Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

[1]  Matthias John,et al.  Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. , 2004, Bioorganic & medicinal chemistry letters.

[2]  Phillip A. Sharp,et al.  The RNAi revolution , 2004, Nature.

[3]  D. Bartel,et al.  MicroRNA-Directed Cleavage of HOXB8 mRNA , 2004, Science.

[4]  Patty J. Lee,et al.  Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis* , 2004, Journal of Biological Chemistry.

[5]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[6]  T. Lyons,et al.  Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. , 2003, Metabolism: clinical and experimental.

[7]  R. Iggo,et al.  Induction of an interferon response by RNAi vectors in mammalian cells , 2003, Nature Genetics.

[8]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[9]  J. Bennett,et al.  Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. , 2003, Molecular vision.

[10]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[11]  A. Ganser,et al.  Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. , 2003, Oligonucleotides.

[12]  C. Llave,et al.  Cleavage of Scarecrow-like mRNA Targets Directed by a Class of Arabidopsis miRNA , 2002, Science.

[13]  J. Burnett,et al.  Apolipoprotein B Metabolism: Tracer Kinetics, Models, and Metabolic Studies , 2002, Critical reviews in clinical laboratory sciences.

[14]  M. Nakamuta,et al.  Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model. , 2000, Human gene therapy.

[15]  S. Young,et al.  Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. , 1999, Journal of lipid research.

[16]  C. Glueck,et al.  Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. , 1997, Metabolism: clinical and experimental.

[17]  Robert V Farese,et al.  Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. , 1995, The Journal of clinical investigation.

[18]  Robert V Farese,et al.  Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Robert V Farese,et al.  Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). , 1993, The Journal of clinical investigation.

[20]  M. Damha,et al.  Oligoribonucleotide synthesis. The silyl-phosphoramidite method. , 1993, Methods in molecular biology.

[21]  S. Beaucage,et al.  3H-1,2-Benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates , 1990 .

[22]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.